Your nails might be trying to tell you something — and checking them could be the easiest way (hands down) to spot hidden ...

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.

A pooled analysis of phase 3 ICONIC data demonstrates that concomitant GLP-1 medication use does not alter skin clearance, ...

Multi-country discrete-choice experiment presented at the Fall Clinical Dermatology Conference demonstrates that skin ...

Eli Lilly and Company presented new exploratory data from its Phase 3b TOGETHER-PsO trial, providing additional insight into the biological psoriasis and obesity and the potential ...

Alumis Inc. announced new Phase 3 data showing that investigational envudeucitinib rapidly and durably improved scalp psoriasis, itching and quality of life in patients with moder ...

Johnson & Johnson (NYSE: JNJ) presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra) in adults and adolescents with moderate-to-severe plaque psoriasis at the Fall ...

Alumis plans to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Over ...

In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity. This analysis examined circulating proteins and gene expression in ...

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor ...

Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading ...